Cargando…
Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177469/ https://www.ncbi.nlm.nih.gov/pubmed/37174130 http://dx.doi.org/10.3390/cancers15092641 |
| _version_ | 1785040645507776512 |
|---|---|
| author | Sankaranarayanan, Ramya Ambur Peil, Jennifer Vogg, Andreas T. J. Bolm, Carsten Terhorst, Steven Classen, Arno Bauwens, Matthias Maurer, Jochen Mottaghy, Felix Morgenroth, Agnieszka |
| author_facet | Sankaranarayanan, Ramya Ambur Peil, Jennifer Vogg, Andreas T. J. Bolm, Carsten Terhorst, Steven Classen, Arno Bauwens, Matthias Maurer, Jochen Mottaghy, Felix Morgenroth, Agnieszka |
| author_sort | Sankaranarayanan, Ramya Ambur |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10177469 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101774692023-05-13 Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 Sankaranarayanan, Ramya Ambur Peil, Jennifer Vogg, Andreas T. J. Bolm, Carsten Terhorst, Steven Classen, Arno Bauwens, Matthias Maurer, Jochen Mottaghy, Felix Morgenroth, Agnieszka Cancers (Basel) Correction MDPI 2023-05-06 /pmc/articles/PMC10177469/ /pubmed/37174130 http://dx.doi.org/10.3390/cancers15092641 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Correction Sankaranarayanan, Ramya Ambur Peil, Jennifer Vogg, Andreas T. J. Bolm, Carsten Terhorst, Steven Classen, Arno Bauwens, Matthias Maurer, Jochen Mottaghy, Felix Morgenroth, Agnieszka Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title | Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title_full | Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title_fullStr | Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title_full_unstemmed | Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title_short | Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230 |
| title_sort | correction: sankaranarayanan et al. auger emitter conjugated parp inhibitor for therapy in triple negative breast cancers: a comparative in-vitro study. cancers 2022, 14, 230 |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177469/ https://www.ncbi.nlm.nih.gov/pubmed/37174130 http://dx.doi.org/10.3390/cancers15092641 |
| work_keys_str_mv | AT sankaranarayananramyaambur correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT peiljennifer correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT voggandreastj correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT bolmcarsten correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT terhorststeven correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT classenarno correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT bauwensmatthias correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT maurerjochen correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT mottaghyfelix correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 AT morgenrothagnieszka correctionsankaranarayananetalaugeremitterconjugatedparpinhibitorfortherapyintriplenegativebreastcancersacomparativeinvitrostudycancers202214230 |